Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?

yalcin, mehmet muhittin; Törüner, Füsun; Bektas, Yasemin; TARLAN, Berçin; Konuk, Onur; YETİMOĞLU, Nial; Coşkun, Meriç; ayvaz, goksun

doi:10.5455/annalsmedres.2023.04.081

Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?

Meriç COŞKUN, (Gazi Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Ankara, Türkiye)

Yasemin Bektas, (Gazi Üniversitesi, Tıp Fakültesi, Ankara, Türkiye)

Nial YETİMOĞLU, (Gazi Üniversitesi, Tıp Fakültesi, Ankara, Türkiye)

Mehmet Muhittin YALÇIN, (Gazi Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Ankara, Türkiye)

Berçin TARLAN, (Gazi Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Onur KONUK, (Gazi Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Füsun BALOŞ TÖRÜNER, (Gazi Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Ankara, Türkiye)

Göksun AYVAZ (Koru Hastanesi, Endokrinoloji ve Metabolizma Klinikleri, Ankara, Türkiye)

Annals of Medical Research

3 2

Yıl: 2023 Cilt: 30 Sayı: 5 Sayfa Aralığı: 617 - 620 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2023.04.081 İndeks Tarihi: 06-06-2023

Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?

Öz:

Aim: Smoking increases the risk of Graves’ orbitopathy (GO) in patients with Graves’ disease (GD). Therefore, smoking cessation should be recommended to all patients with GD. This study aimed to investigate whether smoking cessation recommendations were taken into account in patients with GD and whether there was a difference in terms of smoking cessation between those with and without GO. Materials and Methods: Smoking status of the cases followed up with GD, who were active smokers when diagnosed, were questioned by telephone visit. The relationship of these data with the presence of GO was evaluated. Results: 74 smokers with GD were included in the study. All patients were advised to quit smoking by their physicians. While the number of cigarettes was 20 (10-22)/day at the first visit, the current cigarette use was 7 (0-15)/day, (p<0.001). Forty-nine (66.2%) of the patients had GO. It was found that 49% of patients with GO and 36% of those without GO quit smoking (p=0.28). The decrease in number of cigarettes/day after physician’s recommendation was significantly higher in patients with GO than patients without GO (-95.4% vs. -54.5%), (p=0.02). Conclusion: Although the importance of smoke cessation was emphasized in all patients with GD, we observed that smoking cessation advice was more followed in the GO group in our study. Explaining in detail that smoking in GD may worsen the course of the disease and impair the quality of life in the possible development of GO, may lead patients to consider smoking cessation recommendations more.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ippolito S, Cusini C, Lasalvia P, Gianfagna F, Veronesi G, Gallo D, et al. Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: metaanalysis and meta-regression. Journal of Endocrinological Investigation. 2021 Aug 1;44(8):1707–18.
2. Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, et al. Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Vol. 34, Best Practice and Research: Clinical Endocrinology and Metabolism. Best Pract Res Clin Endocrinol Metab; 2020.
3. Vestergaard P, Rejnmark L, Weeke J, Hoeck HC, Nielsen HK, Rungby J, et al. Smoking as a risk factor for Graves’ disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid. 2002 Jan 1;12(1):69–75.
4. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. European Journal of Endocrinology. 2021 Oct 1;185(4):G43–67.
5. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, KendallTaylor P, Marcocci C, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. In: Thyroid. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA; 2008. p. 333–46.
6. Cao J, Su Y, Chen Z, Ma C, Xiong W. The risk factors for Graves’ ophthalmopathy. Vol. 260, Graefe’s Archive for Clinical and Experimental Ophthalmology. Springer Science and Business Media Deutschland GmbH; 2022. p. 1043–54.
7. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: Impact of smoking severity and current vs lifetime cigarette consumption. Clinical Endocrinology. 1996 Oct 1;45(4):477–81.
8. Xing L, Ye L, Zhu W, Shen L, Huang F, Jiao Q, et al. Smoking was associated with poor response to intravenous steroids therapy in Graves’ ophthalmopathy. British Journal of Ophthalmology. 2015 Dec 1;99(12):1686–91.
9. Kau HC, Wu SB, Tsai CC, Liu CJL, Wei YH. Cigarette Smoke Extract-Induced Oxidative Stress and Fibrosis-Related Genes Expression in Orbital Fibroblasts from Patients with Graves’ Ophthalmopathy. Oxidative Medicine and Cellular Longevity. 2016;2016.
10. Mann K. Risk of smoking in thyroid-associated orbitopathy. In: Experimental and Clinical Endocrinology and Diabetes [Internet]. Exp Clin Endocrinol Diabetes; 1999 [cited 2022 Jun 25]. Available from: https://pubmed.ncbi.nlm.nih.gov/10614913/.
11. Bartalena L. Prevention of Graves’ ophthalmopathy. Vol. 26, Best Practice and Research: Clinical Endocrinology and Metabolism. Baillière Tindall; 2012. p. 371–9.
12. Angelo L, Niederer R, Hart R. Thyroid eye disease in New Zealand: Interaction between ethnicity and smoking status. New Zealand Medical Journal. 2020 Dec;133(1526):12–7.
13. Edmunds MR, Boelaert K. Knowledge of Thyroid Eye Disease in Graves’ Disease Patients With and Without Orbitopathy. Thyroid: official journal of the American Thyroid Association [Internet]. 2019 Apr 1 [cited 2022 Jan 8];29(4):557–62. Available from: https://pubmed.ncbi.nlm.nih.gov/30688164/.
14. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. Vol. 96, Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab; 2011. p. 273–88.
15. Törüner FB, Konuk O, Ayvaz G. Combined Thyroid-Eye Clinics. In: Graves’ Orbitopathy. Karger Publishers; 2017. p. 113–8.
16. de-Arriba-Palomero P, Sales-Sanz M, Fuentemilla E, Won-Kim HR, De-Arriba-Palomero F, Muñoz-Negrete FJ. Effectiveness of oral counselling for smoke cessation in Graves orbitopathy patients. Archivos de la Sociedad Espanola de Oftalmologia. 2019 Jul 1;94(7):323–30.
17. Schatz MJ, McGeehan BC, Maguire MG, Briceño CA. Tobacco counseling in the setting of thyroid eye disease. Arquivos Brasileiros de Oftalmologia. 2022;85(1):13–8.
18. Wiersinga WM. Quality of life in Graves’ ophthalmopathy. Best practice & research Clinical endocrinology & metabolism [Internet]. 2012 Jun [cited 2022 Jan 9];26(3):359–70. Available from: https://pubmed.ncbi.nlm.nih.gov/22632371/
19. Zloto O, Sagiv O, Priel A, Cukierman-Yaffe T, Tirosh A, AgmonLevin N, et al. Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2021 Jul 1;259(7):2009–15.

APA	Coşkun M, Bektas Y, YETİMOĞLU N, yalcin m, TARLAN B, Konuk O, Törüner F, ayvaz g (2023). Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. , 617 - 620. 10.5455/annalsmedres.2023.04.081
Chicago	Coşkun Meriç,Bektas Yasemin,YETİMOĞLU Nial,yalcin mehmet muhittin,TARLAN Berçin,Konuk Onur,Törüner Füsun,ayvaz goksun Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. (2023): 617 - 620. 10.5455/annalsmedres.2023.04.081
MLA	Coşkun Meriç,Bektas Yasemin,YETİMOĞLU Nial,yalcin mehmet muhittin,TARLAN Berçin,Konuk Onur,Törüner Füsun,ayvaz goksun Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. , 2023, ss.617 - 620. 10.5455/annalsmedres.2023.04.081
AMA	Coşkun M,Bektas Y,YETİMOĞLU N,yalcin m,TARLAN B,Konuk O,Törüner F,ayvaz g Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. . 2023; 617 - 620. 10.5455/annalsmedres.2023.04.081
Vancouver	Coşkun M,Bektas Y,YETİMOĞLU N,yalcin m,TARLAN B,Konuk O,Törüner F,ayvaz g Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. . 2023; 617 - 620. 10.5455/annalsmedres.2023.04.081
IEEE	Coşkun M,Bektas Y,YETİMOĞLU N,yalcin m,TARLAN B,Konuk O,Törüner F,ayvaz g "Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?." , ss.617 - 620, 2023. 10.5455/annalsmedres.2023.04.081
ISNAD	Coşkun, Meriç vd. "Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?". (2023), 617-620. https://doi.org/10.5455/annalsmedres.2023.04.081

APA	Coşkun M, Bektas Y, YETİMOĞLU N, yalcin m, TARLAN B, Konuk O, Törüner F, ayvaz g (2023). Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. Annals of Medical Research, 30(5), 617 - 620. 10.5455/annalsmedres.2023.04.081
Chicago	Coşkun Meriç,Bektas Yasemin,YETİMOĞLU Nial,yalcin mehmet muhittin,TARLAN Berçin,Konuk Onur,Törüner Füsun,ayvaz goksun Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. Annals of Medical Research 30, no.5 (2023): 617 - 620. 10.5455/annalsmedres.2023.04.081
MLA	Coşkun Meriç,Bektas Yasemin,YETİMOĞLU Nial,yalcin mehmet muhittin,TARLAN Berçin,Konuk Onur,Törüner Füsun,ayvaz goksun Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. Annals of Medical Research, vol.30, no.5, 2023, ss.617 - 620. 10.5455/annalsmedres.2023.04.081
AMA	Coşkun M,Bektas Y,YETİMOĞLU N,yalcin m,TARLAN B,Konuk O,Törüner F,ayvaz g Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. Annals of Medical Research. 2023; 30(5): 617 - 620. 10.5455/annalsmedres.2023.04.081
Vancouver	Coşkun M,Bektas Y,YETİMOĞLU N,yalcin m,TARLAN B,Konuk O,Törüner F,ayvaz g Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?. Annals of Medical Research. 2023; 30(5): 617 - 620. 10.5455/annalsmedres.2023.04.081
IEEE	Coşkun M,Bektas Y,YETİMOĞLU N,yalcin m,TARLAN B,Konuk O,Törüner F,ayvaz g "Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?." Annals of Medical Research, 30, ss.617 - 620, 2023. 10.5455/annalsmedres.2023.04.081
ISNAD	Coşkun, Meriç vd. "Is our recommendation for smoking cessation considered in patients with Graves disease and Graves orbitopathy?". Annals of Medical Research 30/5 (2023), 617-620. https://doi.org/10.5455/annalsmedres.2023.04.081